Tun A, Khan I A, Win M T, Hussain A, Hla T A, Wattanasuwan N, Vasavada B C, Sacchi T J
Division of Cardiology, Department of Medicine, Long Island College Hospital, Brooklyn, N.Y., USA.
Cardiology. 1998;90(4):280-5. doi: 10.1159/000006859.
The objectives of this study were: (1) to evaluate the specificity of cardiac troponin I and creatine kinase-MB isoenzyme in ambulatory asymptomatic chronic renal failure patients on long-term hemodialysis, and (2) to evaluate the effect of hemodialysis on the serum levels of cardiac troponin I and creatine kinase-MB isoenzyme.
One hundred and forty-four consecutive ambulatory asymptomatic chronic renal failure patients on hemodialysis for a minimum of 1 year were evaluated clinically. Serum cardiac troponin I and creatine kinase-MB isoenzyme levels were measured with specific monoclonal antibodies before and after dialysis using ACCESS Troponin I and ACCESS CK-MB assays.
The specificity of serum cardiac troponin I was 83% with a cutoff level of 0.03 ng/ml, which is an expected level for healthy population, but it rose to 100% with a cutoff level of 0.15 ng/ml, which is a reference level for patients with acute myocardial infarction. Twenty-four (17%) patients had borderline elevation in cardiac troponin I (>0.03 to <0.15 ng/ml). A history of angina pectoris was more common in the borderline-elevated cardiac troponin I subgroup. In 28% of the patients, serum creatine kinase-MB isoenzyme levels were increased with a specificity of 72% at a cutoff level of 4 ng/ml, which is the upper limit of normal, but the specificity rose to 98% by increasing the cutoff level value to 10 ng/ml. There were no statistically significant differences in serum levels of cardiac troponin I and creatine kinase-MB isoenzyme before and after dialysis.
Cardiac troponin I is highly specific in ambulatory asymptomatic chronic renal failure patients on long-term hemodialysis; borderline elevations in cardiac troponin I may represent microinjury to the myocardium. A serum level of creatine kinase-MB isoenzyme >2.5 times of the normal upper limit may be highly specific in this patient population. Hemodialysis per se does not significantly change the serum levels of cardiac troponin I and creatine kinase-MB isoenzyme.
本研究的目的是:(1)评估肌钙蛋白I和肌酸激酶-MB同工酶在长期血液透析的非卧床无症状慢性肾衰竭患者中的特异性,以及(2)评估血液透析对血清肌钙蛋白I和肌酸激酶-MB同工酶水平的影响。
对144例连续进行血液透析至少1年的非卧床无症状慢性肾衰竭患者进行临床评估。使用ACCESS肌钙蛋白I和ACCESS CK-MB检测法,在透析前后用特异性单克隆抗体测量血清肌钙蛋白I和肌酸激酶-MB同工酶水平。
血清肌钙蛋白I的特异性在临界值为0.03 ng/ml时为83%,这是健康人群的预期水平,但在临界值为0.15 ng/ml时升至100%,这是急性心肌梗死患者的参考水平。24例(17%)患者的肌钙蛋白I临界升高(>0.03至<0.15 ng/ml)。心绞痛病史在肌钙蛋白I临界升高亚组中更为常见。28%的患者血清肌酸激酶-MB同工酶水平升高,在临界值为4 ng/ml(正常上限)时特异性为72%,但将临界值提高到10 ng/ml时特异性升至98%。透析前后血清肌钙蛋白I和肌酸激酶-MB同工酶水平无统计学显著差异。
肌钙蛋白I在长期血液透析的非卧床无症状慢性肾衰竭患者中具有高度特异性;肌钙蛋白I临界升高可能代表心肌微损伤。血清肌酸激酶-MB同工酶水平>正常上限2.5倍在该患者群体中可能具有高度特异性。血液透析本身不会显著改变血清肌钙蛋白I和肌酸激酶-MB同工酶水平。